Antitumour Potential of a Polysaccharide-rich Substance from the Fruit Juice of Morinda citrifolia (Noni) on Sarcoma 180 Ascites Tumour in Mice

Phytotherapy Research

Volumn 17, Issue 10, 2003, Pages 1158-1164

  Furusawa, Eiichi ^a   Hirazumi, Anne ^a,b   Story, Stephen ^b   Jensen, Jarakae ^b  

^a UNIVERSITY OF HAWAII   (United States)

^b Department of R and D   (United States)

Author keywords

Antitumour; Fruit juice; Immunomodulator; Morinda citrifolia; Polysaccharide; Sarcoma 180 ascites tumour

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IMEXON; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; METHOTREXATE; MITOMYCIN C; MORINDA CITRIFOLIA EXTRACT; PACLITAXEL; PLANT EXTRACT; PYRAN COPOLYMER; TIOGUANINE; VINCRISTINE;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES TUMOR; BODY WEIGHT; CANCER CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FRUIT JUICE; IMMUNOMODULATION; MALE; MORINDA CITRIFOLIA; MOUSE; NONHUMAN; SARCOMA; SARCOMA 180; SURVIVAL RATE; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DRUG SYNERGISM; FEMALE; FRUIT; KILLER CELLS, NATURAL; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED STRAINS; MORINDA; PHYTOTHERAPY; PLANT EXTRACTS; POLYSACCHARIDES; SARCOMA 180; T-LYMPHOCYTES;

MORINDA; MORINDA CITRIFOLIA;

EID: 0346095663     PISSN: 0951418X     EISSN: None     Source Type: Journal    
DOI: 10.1002/ptr.1307     Document Type: Article

References (40)

1. Arulanandam BP, Mittler JN, Lee WT, O'Toole M, Metger DW. 2000. Neonatal administration of IL-12 enhances the protective efficacy of antiviral vaccines. J Immunol 164: 3698-3704.
2. Bibby CM. 1999. Making the most of rodent tumour systems in cancer drug discovery. Br J Cancer 79: 1633-1640.
3. Chirigos MA, Ussery MA, Rankin JT, Herrmann D, Bicker U, Black PL. 1990. Antiviral efficacy of imexon in the Rauscher murine retrovirus AIDS model. Immunopharmacol Immunotoxicol 12: 1-21.
4. Corbett TH, Valeruote FA, Demchik Patherson GML, Moore RE. 1996. Preclinical anticancer activity of cryptophycin-8. J Exp Ther Oncol 1: 95-108.
5. DiPadova FE. 1989. Pharmacology of cyclosporine (Sandimmune) V. Pharmacological effects on immune function: in vitro studies. Pharmacol Rev 41: 373-405.
6. Fujihara M, lizima N, Yamamoto I, Nagumo T. 1984. Purification and chemical and physical characterization of an antitumor polysaccharide from the brown seaweed Sargassum fulvellum. Carbohydr Res 125: 97-106.
7. Furusawa E, Chou SC, Furusawa S, Hirazumi A, Dang Y. 1992. Antitumour activity of Ganoderma lucidum, an edible mushroom, on intraperitoneally implanted Lewis lung carcinoma in syngeneic mice. Phytother Res 6: 300-304.
8. Furusawa E, Furusawa S. 1988. Effect of pretazettine and Viva-Natural, a dietary seaweed extract, on spontaneous AKR leukemia in comparison with standard drugs. Oncology 45: 180-186.
9. Furusawa E, Furusawa S. 1989. Anticancer potential of Viva-Natural, a dietary seaweed extract, on Lewis lung carcinoma in comparison with chemical immunomodulators and cyclosporine-accelerated AKR leukemia. Oncology 46: 343-349.
10. Furusawa E, Furusawa S. 1990. Antitumor potential of low-dose chemotherapy manifested in combination with immunotherapy of Viva-Natural, a dietary seaweed extract, on Lewis lung carcinoma. Cancer Lett 50: 71-78.
11. Goto S, Sato M, Kaneko K, Itoh M, Sato S, Takeuchi S. 1999. Analysis of Th1 and Th2 cytokine production by peripheral blood mononuclear cells as a parameter of immunological dysfunction in advanced cancer patients. Cancer Immunol Immunother 48: 435-442.
12. Hirazumi A, Furusawa E. 1999. An immunomodulatory polysaccharide-rich substance from the fruit juice of Morinda citrifolia (Noni) with antitumour activity. Phytother Res 13: 330-387.
13. Hirazumi A, Furusawa E, Chou SC, Hokama Y. 1994. Anticancer activity of Morinda citrifolia on intraperitoneally implanted Lewis lung carcinoma in syngeneic mice. Proc West Pharmacol Soc 37: 145-146.
14. Hirazumi A, Furusawa E, Chou SC, Hokama Y. 1996. Immunomodulation contributes to anticancer activity of Morinda citrifolia (Noni) fruit juice. Proc West Pharmacol Soc 39: 7-9.
15. Hirazumi A, Furusawa E, Chou SC, Okano C, Ching C. 1992. Antitumor activity of Morinda citrifolia on intraperitoneally implanted Lewis lung carcinoma in mice. Proc Am Soc Cancer Res 33: 515.
16. Huhn RD, Pennline K, Radwanski E, Clarke L, Sabo R, Cutler DL. 1999. Effects of single intravenous doses of recombinant human interleukin-10 on subsets of circulating leukocytes in humans. Immunopharmacology 41: 109-117.
17. Ishii KJ, Weiss WR, Ichino M, Verthelyi D, Klinman DM. 1999. Activity and safety of DNA plasmids encoding IL-4 and IFN gamma. Gene Ther 6: 237-244.
18. Iwasaki M, Yu WG, Uekusa Y, Hamaoka T. 2000. Differential IL-12 responsiveness of T cells but not of NK cells from tumor-bearing mice in IL-12-responsive versus -unresponsive tumor models. Int Immunol 12: 701-709.
19. Jani JP, Mistry JS, Morris G, Davies P, Lazo JS, Sebti M. 1992. In vivo circumvention of human colon carcinoma resistance to bleomycin. Cancer Res 52: 2931-2937.
20. Kaneda N, Nafata H, Furuta T, Yokokura T. 1990. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 50: 1715-1720.
21. Kaneda Y, Yamamoto Y, Kamada H, et al. 1998. Antitumor activity of tumor necrosis factor alpha conjugated with divinyl ether and maleic anhydride copolymer on solid tumors in mice. Cancer Res 58: 290-295.
22. Kaufman HL, Rao JB, Irivine KR, Bronte V, Rosenberg SA, Restifo NP. 1999. Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxrisu-based vaccine in an experimental murine tumor model. J Immunother 22: 489-496.
23. Kikuchi T, Joki T, Abe T, Ohno T. 1999a. Antitumor activity of killer cells stimulated with both interleukin-2 and interleukin-12 on mouse glioma cells. J Immunol 22: 245-250.
24. Kikuchi T, Joki T, Saitoh S, Ohno T. 1999b. Antitumor activity of interleukin-2-producing tumor cells and recombinant interleukin-12 against mouse glioma cells located in the central nervous system. Int J Cancer 80: 425-430.
25. Kim BG, Joo HG, Chung IS, Chung HY, Woo HJ, Yun YS. 2000. Inhibition of interleukin-10 (IL-10) production from MOPC 315 tumor cells by IL-10 antisense oligodeoxynucleotides enhances cell-mediated immune responses. Cancer Immunol Immunother 49: 433-440.
26. Kimura K, Nishimura H, Matsuzaki T, Yokokura T, Nimura Y, Yoshikai Y. 2000. Synergistic effect of interleukin-15 and interleukin-12 on antitumor activity in a murine malignant pleurisy model. Cancer Immunol Immunother 49: 71-77.
27. Li LH, DeKoning TF, Wallace TL. 1987. Relationship between modulation of natural killer cell activity and antitumor activity of bropirimine when used in combination with various types of chemotherapeutic drugs. Cancer Res 47: 5894-5900.
28. Nakajima C, Uekusa Y, Iwasaki M, Hamaoka T. 2001. A role of interferon-r (IFN-r) in tumor immunity: T cells with the capacity to reject tumor cells are generated but fail to migrate to tumor sites in IFN-r-deficient mice. Cancer Res 6: 3399-3405.
29. + T cells. Immunology 103: 281-290.
30. Parkins C, Denekamp J, Chaplin DJ. 1993. Enhancement of mitomycin-C cytotoxicity by combination with flavone acetic acid in a murine tumour. Anticancer Res 13: 1437-1442.
31. Schultz RM, Tang JC, Delong DC, Ades EW, Altom MG. 1986. Inability of anti-asialo-GM1 and 2-chloroadenosine to abrogate maleic anhydride-divinyl ether-induced resistance against experimental murine carcinoma metastases. Cancer Res 46: 5624-5628.
32. Shiau AL, Lin CY, Tzai TS, Wu CL. 2001. Postoperative immunogene therapy of murine bladder tumor by in vitro administration of retroviruses expressing mouse interferon-r. Cancer Gene Ther 8: 73-81.
33. Song K, Chang Y, Prud'homme GJ. 2000. Regulation of T-helper-1 versus T-helper-2 activity and enhancement of tumor immunity by combined DNA-based vaccination and nonviral cytokine gene transfer. Gene Ther 7: 481-492.
34. Sun H, Guitierrez P, Jackson MJ, Kundu N, Fulton AM. 2000. Essential role of nitric oxide and interferon-r for tumor immunotherapy with interleukin-10. J Immunother 23: 208-214.
35. Taylor CW, LeBianc M, Fisher RI, Miller TP. 2000. Phase II evaluation of interleukin-4 in patients with non-Hodgkin's lymphoma: a SWOG trial. Anti-Cancer Drugs 11: 695-700.
36. TenHagen TLM, vanVianen W, Savelkoul HFJ, Bakker-Woudenberg IAJM. 1998. Involvement of T cells in enhanced resistance to Klebsiella pneumoniae septicemia in mice treated with liposome-encapsulated muramyl tripeptide phosphatidyl-ethanolamine or gamma interferon. Infect Immunity 66: 1962-1967.
37. Trinchieri G. 1995. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge inrate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 13: 251-276.
38. Verloes R, Atassi G, Dumont P, Kanarek L. 1981. Successful immunotherapy with micrococcus, BCG or related polysaccharides on L1210 leukemia after BCNU chemotherapy. Br J Cancer 43: 201-209.
39. Xu X, Fu XY, Plate J, Chong ASF. 1998. Interferon-r induces cell protein for up-regulation of Fas and FasL expression. Cancer Res 58: 2832-2837.
40. Zidek Z, Frankova D. 1999. Interleukin-10 in combination with interferon-r and tumor necrosis factor-a enhances in vitro production of nitric oxide by murine resident peritoneal macrophages. Eur Cytokine Netw 10: 25-32.